- ►diabetesjournals.org YS Lee, S Shin, T Shigihara, E Hahm, MJ Liu … - Diabetes, 2007 - Am Diabetes Assoc Long-term treatment with glucagon-like peptide (GLP)-1 or its analog can improve
insulin sensitivity. However, continuous administration is required due to its
short half-life. We hypothesized that continuous production of therapeutic ... Cited by 16 - Related articles - BL Direct - All 6 versions
GB Parsons, DW Souza, H Wu, D Yu, SG … - Gene Therapy, 2006 - nature.com Glucagon-like peptide 1 (GLP-1) is a promising candidate for the treatment of
type II diabetes. However, the short in vivo half-life of GLP-1 has made
peptide-based treatments challenging. Gene therapy aimed at achieving ... Cited by 9 - Related articles - BL Direct - All 4 versions
S Oh, M Lee, K Ko - US Patent App. 12/074,865, 2008 - Google Patents US 20090227660A1 (i9) United States (12) Patent Application Publication oo) Pub.
No.: US 2009/0227660 Al Oh et al. (43) Pub. Date: Sep. 10,2009 (54) GLP-1 GENE
DELIVERY FOR THE TREATMENT OF TYPE 2 DIABETES (76) Inventors: Seungjoon Oh, ... Cited by 18 - Related articles - BL Direct - All 11 versions
H Gao, X Wang, Z Zhang, Y Yang, J Yang, X … - Endocrine, 2007 - Springer Abstract Glucagon-like peptide-1 (7–36) amide (GLP-1) is an insulin
secretagogue. Recently, many studies have shown GLP-1 can improve insulin
resistance in peripheral tissues. In the present study, we investigated ... Cited by 3 - Related articles - BL Direct - All 2 versions
M Kumar, Y Hunag, Y Glinka, GJ Prud' … - Gene therapy, 2006 - nature.com Glucagon-like peptide (GLP-1), a major physiological incretin, plays numerous
important roles in modulating blood glucose homeostasis and has been proposed
for the treatment of type 2 diabetes. The major obstacles for using native ... Cited by 23 - Related articles - BL Direct - All 5 versions
L Li, G Yang, Q Li, X Tan, H Liu, Y Tang, G … - Diabetes Obes Metab, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 6 - Related articles - All 2 versions
SP Chang, YH Chen, WC Chang, IM Liu, JT … - Life sciences, 2006 - Elsevier Effects of endurance training on the phosphoenolpyruvate carboxykinase (PEPCK),
a rate-limiting enzyme of gluconeogenesis, were studied in the obese Zucker
rats. We used a moderate exercise program consisting of treadmill running ... Cited by 5 - Related articles - All 4 versions
[CITATION] Sitagliptin, a selective DPP-4 Inhibitor, is well tolerated in patients with type 2 diabetes: …
MJ Liu, S Shin, N Li, T Shigihara, YS Lee, JW … - Molecular Therapy, 2007 - nature.com Type 1 diabetes results from insulin deficiency caused by destruction of
pancreatic cells. Glucagon-like peptide (GLP)-1 stimulates cell growth and
differentiation. To determine whether continuous expression of GLP-1 in ... Cited by 9 - Related articles - All 2 versions
CF Nagell, A Wettergren, C Ørskov, JJ Holst - Scandinavian journal of gastroenterology, 2006 - informahealthcare.com Background. Glucagon-like peptide 1 (GLP-1) is an intestinal hormone that is
secreted in response to meal ingestion. GLP-1 inhibits gastric emptying and
reduces postprandial gastric secretion and may play a physiological ... Cited by 12 - Related articles - BL Direct - All 7 versions
